Nigeria, May 8 -- OpenAI has been meeting with the U.S. Food and Drug Administration to talk about how artificial intelligence could help improve the way drugs are reviewed.

The discussions, which were recently reported by Wired, focused on a project known as cderGPT, believed to be designed for use by the Center for Drug Evaluation.

This FDA department handles the regulation of both prescription and over-the-counter drugs in the country.

The idea behind these meetings is to explore how AI can make certain parts of the drug approval process faster.

Drug development is known to take several years, often more than a decade, before a product is fully approved.

With AI involved, the hope is to reduce delays near the final stages of evalu...